[Hormonal contraception and cervix of the uterus pathology]. 2007

m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia

The effect of hormonal contraception on cervix of the uterus of young nullipara women with ectopia was investigated. Cohort study was carried out by using simple blind method. By means of statistical data manipulation correlation between the application of hormonal contraceptives and changes of colposcopy pictures in the zone of pathology was displayed. Excluton showed low percent anomalous colpscopy picture in pathology zone. Excluton was declared as medicine of choice for nullipara women with ectopia. Still it is necessary to conduct a strong dynamic control of cervix of the uterus (colposcopy and pap-smear test) in order to avoid complications.

UI MeSH Term Description Entries
D008234 Lynestrenol A synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL). 19-Norpregn-4-en-20-yn-17-ol, (17alpha)-,Ethinylestrenol,Exluton,Linesterol,Linestrenol,Lynestrenol, (9 beta, 10 alpha,17 alpha)-Isomer,Lynoestrenol
D002578 Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE. Cervical Dysplasia,Cervical Intraepithelial Neoplasia,Cervix Dysplasia,Dysplasia of Cervix Uteri,Neoplasia, Cervical Intraepithelial,Cervical Intraepithelial Neoplasia, Grade III,Cervical Intraepithelial Neoplasms,Intraepithelial Neoplasia, Cervical,Cervical Dysplasia, Uterine,Cervical Dysplasias,Cervical Intraepithelial Neoplasm,Cervix Uteri Dysplasia,Cervix Uteri Dysplasias,Dysplasia, Cervical,Dysplasia, Cervix,Dysplasia, Uterine Cervical,Intraepithelial Neoplasm, Cervical,Intraepithelial Neoplasms, Cervical,Neoplasm, Cervical Intraepithelial,Neoplasms, Cervical Intraepithelial
D003278 Contraceptives, Oral, Hormonal Oral contraceptives which owe their effectiveness to hormonal preparations. Hormonal Oral Contraceptive,Hormonal Oral Contraceptive Agent,Contraceptive Agents, Estrogen,Contraceptive Agents, Oral, Hormonal,Hormonal Oral Contraceptive Agents,Oral Contraceptive Agents, Hormonal,Oral Contraceptives, Hormonal,Contraceptive, Hormonal Oral,Contraceptives, Hormonal Oral,Estrogen Contraceptive Agents,Hormonal Oral Contraceptives,Oral Contraceptive, Hormonal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D017135 Desogestrel A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents (ORAL CONTRACEPTIVES, COMBINED). 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17alpha)-,13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol,Cerazette,Marvelon,Org-2969,13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol,Org 2969,Org2969,alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17

Related Publications

m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
December 2006, Georgian medical news,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
January 1985, Contraception, fertilite, sexualite,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
December 1997, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
December 1991, Akusherstvo i ginekologiia,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
June 1986, Advances in contraception : the official journal of the Society for the Advancement of Contraception,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
May 2005, American journal of obstetrics and gynecology,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
March 2021, Journal of pathology and translational medicine,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
January 1988, Arkhiv patologii,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
April 2018, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia,
m A Dzhangidze, and M G Dznugeli, and N G Museridze, and L K Zakaraia
January 1981, Jugoslavenska ginekologija i opstetricija,
Copied contents to your clipboard!